LeMaitre Vascular, Inc.
LMATNASDAQHealthcare● Active
$94.73
+$0.25(+0.27%)
Market Cap$2.2B
P/E Ratio—
52W High$118.01
52W Low$79.01
LeMaitre Vascular, Inc. (LMAT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LMAT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
$0.68
Est. $0.66 · +3.0%
Revenue
$0.07B
Est. $0.07B · -0.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat EPS🔥 4-Quarter EPS Beat Streak
LMAT reports quarterly as a NASDAQ-listed Medical - Instruments & Supplies company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | $0.81 | — | — | — | $0.07B | — |
| ▲ Q2 FY2026 | May 5, 2026 | $0.66 | $0.68 | +3.0% | $0.07B | $0.07B | -0.2% |
| ▲ Q1 FY2026 | Feb 25, 2026 | $0.67 | $0.68 | +1.5% | $0.06B | $0.06B | +2.6% |
| ▲ Q4 FY2025 | Nov 6, 2025 | $0.56 | $0.62 | +9.9% | $0.06B | $0.06B | -1.8% |
| ▲ Q3 FY2025 | Aug 5, 2025 | $0.57 | $0.60 | +5.3% | $0.06B | $0.06B | +5.5% |
| ▼ Q2 FY2025 | May 1, 2025 | $0.50 | $0.48 | -4.0% | $0.06B | $0.06B | +3.9% |
| — Q1 FY2025 | Feb 27, 2025 | $0.49 | $0.49 | +0.0% | $0.06B | $0.06B | -0.5% |
| ▲ Q4 FY2024 | Oct 31, 2024 | $0.44 | $0.49 | +11.4% | $0.05B | $0.06B | -2.1% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
$0.81
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Beat
EPS Actual
$0.68
EPS Est.
$0.66
EPS Surpr.
+3.0%
Revenue
$0.07B
Q1 FY2026
Feb 25, 2026Beat
EPS Actual
$0.68
EPS Est.
$0.67
EPS Surpr.
+1.5%
Revenue
$0.06B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
$0.62
EPS Est.
$0.56
EPS Surpr.
+9.9%
Revenue
$0.06B
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
$0.60
EPS Est.
$0.57
EPS Surpr.
+5.3%
Revenue
$0.06B
Q2 FY2025
May 1, 2025Miss
EPS Actual
$0.48
EPS Est.
$0.50
EPS Surpr.
-4.0%
Revenue
$0.06B
Q1 FY2025
Feb 27, 2025
EPS Actual
$0.49
EPS Est.
$0.49
EPS Surpr.
+0.0%
Revenue
$0.06B
Q4 FY2024
Oct 31, 2024Beat
EPS Actual
$0.49
EPS Est.
$0.44
EPS Surpr.
+11.4%
Revenue
$0.05B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.88 | $0.90 | $0.91 | 2 |
| Q3 FY2028 | $0.85 | $0.86 | $0.87 | 2 |
| Q2 FY2028 | $0.87 | $0.88 | $0.89 | 2 |
| Q1 FY2028 | $0.81 | $0.83 | $0.84 | 2 |
| Q4 FY2027 | $0.84 | $0.85 | $0.86 | 1 |
| Q3 FY2027 | $0.79 | $0.80 | $0.81 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +3.0% | $111.53 | $112.00 | +0.42% |
| ▲ Q1 FY2026 | Feb 25, 2026 | +1.5% | $90.75 | $91.38 | +0.69% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +9.9% | $86.27 | $85.60 | -0.78% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +5.3% | $84.36 | $85.60 | +1.47% |
| ▼ Q2 FY2025 | May 1, 2025 | -4.0% | $90.74 | $90.24 | -0.55% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +0.0% | $103.05 | $99.91 | -3.05% |
| ▲ Q4 FY2024 | Oct 31, 2024 | +11.4% | $89.05 | $88.39 | -0.74% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +10.6% | $86.89 | $86.25 | -0.74% |
Q2 FY2026+0.42%
Report Date
May 5, 2026
EPS Beat/Miss
+3.0%
Price Before
$111.53
Price After
$112.00
Q1 FY2026+0.69%
Report Date
Feb 25, 2026
EPS Beat/Miss
+1.5%
Price Before
$90.75
Price After
$91.38
Q4 FY2025-0.78%
Report Date
Nov 6, 2025
EPS Beat/Miss
+9.9%
Price Before
$86.27
Price After
$85.60
Q3 FY2025+1.47%
Report Date
Aug 5, 2025
EPS Beat/Miss
+5.3%
Price Before
$84.36
Price After
$85.60
Q2 FY2025-0.55%
Report Date
May 1, 2025
EPS Beat/Miss
-4.0%
Price Before
$90.74
Price After
$90.24
Q1 FY2025-3.05%
Report Date
Feb 27, 2025
EPS Beat/Miss
+0.0%
Price Before
$103.05
Price After
$99.91
Q4 FY2024-0.74%
Report Date
Oct 31, 2024
EPS Beat/Miss
+11.4%
Price Before
$89.05
Price After
$88.39
Q3 FY2024-0.74%
Report Date
Aug 1, 2024
EPS Beat/Miss
+10.6%
Price Before
$86.89
Price After
$86.25
Avg Beat Reaction-0.39%
Avg Miss Reaction-0.55%
Beat Rate7 / 8 quarters
Largest Move-3.05% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LMAT ends December
LeMaitre Vascular, Inc. (LMAT) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $0.68 — beating the analyst consensus of $0.66 by +3.0%. LMAT has beaten EPS estimates for 4 consecutive quarters. The next LMAT earnings date is expected around September 1, 2026.
Each quarter, investors track LMAT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LMAT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LMAT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LMAT earnings · 5 questionsLeMaitre Vascular, Inc.'s next earnings report is expected around September 1, 2026. LMAT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LMAT historically reports after market close (AMC).
LMAT earnings datewhen is LMAT earningsLMAT next earnings datewhen does LMAT report earningsLMAT earnings calendar
▸ Source: FMP · LeMaitre Vascular, Inc. SEC filings · US GAAP · LeMaitre Vascular, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026